SearchSearch results for: “”

Advising a transport organisation on the implementation of new regulation standards.

Advising a financial organisation how to avoid the publication of a sanction imposed by the regulator.

Stibbe advises Accor on the sale and franchise-back of 29 hotels in the Netherlands and Germany for a total value of €234 million.

Advising J.P. Morgan and the other underwriters on the notes offerings of Fiat Chrysler Automobiles N.V. for a total amount of USD 3.0 billion.

Representing the Belgian Ministry of Economy in a high-profile lawsuit against SABAM (the Belgian Society of Authors, Composers and Publishers) before the Brussels courts concerning the private collecting society’s compliance with the Belgian Copyright Ac

Providing legal assistance to several companies with regard to investigations of the Social Affairs and Employment Inspectorate (SAE, in Dutch: Inspectie Sociale Zaken en Werkgelegenheid) and imposed fines under the Foreign Nationals (Employment) Act. 

Stibbe advises NRG Value, a Dutch fuel and convenience retail management chain recently started by former managers from Shell, Exxon Mobil and Merrill Lynch, on its acquisition of 107 Esso petrol stations from Esso Nederland, a subsidiary of Exxon Mobil.

Stibbe advises J.P. Morgan and the other underwriters on the equity offering of Fiat Chrysler Automobiles N.V.

Advising the underwriters on the USD 1 billion convertible bond offering of NXP Semiconductors

Stibbe advises Tornier N.V. on its merger with Wright Medical Group, Inc. in an all stock transaction with a combined equity value of approximately $3.3 billion.

Stibbe advises Pershing Square Holdings, Ltd. on the IPO of this investment fund managed by the leading active investor Bill Ackmann.

Stibbe advises Intermixt as the representative of the Flemish municipalities of the so-called mixed energy distribution sector with respect to the withdrawal of Electrabel from the Flemish electricity and gas distribution system operators.

Stibbe advises Mylan Inc., the pharmaceuticals company listed on the NASDAQ with a market cap of approximately $19 billion, on the inversion acquisition of Abbott’s non-U.S. developed markets specialty and branded generics business.